数据
资源
版本对比
免费注册
预约演示
免费注册
Ascendis Pharma
Announces Strategic Partnership with
Teijin Limited
in Japan
2023-11-29
·
BioSpace
引进/卖出
Teijin
to receive exclusive license to further develop and commercialize
TransCon
™ hGH,
TransCon
™ PTH, and
TransCon
™ CNP in Japan
Ascendis Pharma
is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones
Ascendis Pharma
is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) --
Ascendis Pharma A/S
(Nasdaq: ASND) today announced that the company has entered into an exclusive license agreement with
Teijin Limited
for the further development and commercialization of
TransCon hGH
,
TransCon
TransCon PTH
, and
TransCon
TransCon CNP
for endocrinology rare disease in Japan. “We are pleased to partner with
Teijin Pharma
given their track record of navigating regulatory approval and commercialization of rare disease and endocrinology product candidates in Japan, and commitment to providing best-in-class therapies,” said Jan Mikkelsen,
Ascendis Pharma
’s President and Chief Executive Officer. “We believe this collaboration is a major step in our journey to achieve global reach for our current Endocrinology Rare Disease portfolio by helping to address unmet medical needs of patients in Japan.” “
Ascendis
has leveraged its innovative
TransCon
technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio,” said Akimoto Uchikawa,
Teijin Limited
’s President and Chief Executive Officer. “We expect this partnership will contribute a great deal to advance our healthcare business vision to address issues of patients, families and communities in need of more support followed by the introduction of pharmaceuticals in rare and intractable disease areas utilizing our business platform cultivated so far.” Under the terms of the agreement,
Ascendis
will receive an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition,
Ascendis Pharma
is eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product. About
Ascendis Pharma A/S
Ascendis Pharma
is applying its innovative
TransCon
technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion,
Ascendis
uses its
TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis
is headquartered in Copenhagen, Denmark and has additional facilities in Germany (Heidelberg and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Please visit ascendispharma.com to learn more. About the
Teijin Group
Teijin
(TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer,
Teijin
today comprises some 170 companies employing 20,000 people in 20 countries. Through “Human Chemistry,
Human Solutions
,”
Teijin
relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities.
Teijin
posted consolidated sales of JPY 1,018.8 billion (USD 7.6 billion) and total assets of JPY 1,242.4 billion (USD 9.2 billion) in the fiscal year ending March 31, 2023. Please visit to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding
Ascendis
’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i)
Ascendis
’ potential receipt of milestone and royalty payments from its strategic partnership with
Teijin
, (ii)
Ascendis
’ ability to achieve global reach for its current Endocrinology Rare Disease portfolio, (iii) the best-in-class potential for
Ascendis
’ products and the ability of
Ascendis
’ products to complement
Teijin
’s existing portfolio, (iv) the ability for the partnership between
Ascendis
and
Teijin
to advance
Teijin
’s healthcare business vision, (v)
Ascendis
’ ability to apply its platform technology to build a leading, fully integrated global biopharma company, and (vi)
Ascendis
’ use of its
TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis
may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that
Ascendis
makes, including the following: dependence on third party manufacturers, distributors and service providers for
Ascendis
’ products and product candidates; unforeseen safety or efficacy results in
Ascendis
’ development programs or on-market products; unforeseen expenses related to commercialization of any approved
Ascendis
products; unforeseen expenses related to
Ascendis
’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and
Ascendis
’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays;
Ascendis
’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to
Ascendis
’ business in general, see
Ascendis
’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and
Ascendis
’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that
Ascendis
may enter into or make.
Ascendis
does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis
,
Ascendis Pharma
, the
Ascendis Pharma
logo, the company logo, and
TransCon
, are trademarks owned by the
Ascendis Pharma group
. © November 2023
Ascendis Pharma A/S
. Investor Contacts: Tim Lee
Ascendis Pharma
+1 (650) 374-6343 tle@ascendispharma.com ir@ascendispharma.com Media Contact: Melinda Baker
Ascendis Pharma
+1 (650) 709-8875 media@ascendispharma.com Patti Bank ICR Westwicke +1 (415) 513-1284 patti.bank@westwicke.com
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Ascendis Pharma A/S
Teijin Ltd.
Transcon Valladolid SA
[+3]
适应症
-
靶点
-
药物
隆培促生长素
帕罗培特立帕肽
TransCon CNP
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
2024年3月全球首批及特殊审评药物报告
智慧芽生物医药
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
2024年2月全球首批及特殊审评药物报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务